26
total announcements
500124.BO · 15 min delayed
Dr Reddys Laboratories Ltd
Dr Reddys Laboratories Ltd has allotted 4,110 equity shares to eligible employees on exercise of stock options under ESOPs, as per Regulation 30 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015.
Dr Reddys Laboratories Ltd
Dr Reddys Laboratories Ltd has published a newspaper notice regarding loss of share certificates, and the company has made the notice available on its website and on the websites of the stock exchanges.
Dr Reddys Laboratories Ltd
Dr Reddys Laboratories Ltd has disclosed a GMP inspection by the USFDA at its formulations manufacturing facility in Hyderabad, with four observations issued in a Form 483, which the company will address within the stipulated timeline.
Dr Reddys Laboratories Ltd
Dr Reddys Laboratories Ltd has informed that the USFDA has classified the inspection outcome at its API manufacturing facility in Mirfield, West Yorkshire, United Kingdom as 'Voluntary Action Indicated (VAI)' and concluded that the inspection is officially closed.
Dr Reddys Laboratories Ltd
Dr Reddys Laboratories Ltd has received a disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 from ICICI Prudential Mutual Fund.
Dr Reddys Laboratories Ltd
Dr Reddys Laboratories Ltd has announced the resignation of Mr. Deepak Sapra as CEO, API and Services and Senior Management Personnel, effective November 12, 2026.
Dr Reddys Laboratories Ltd
Dr. Reddy's Laboratories Ltd has terminated its agreement with Novartis India Limited due to a change in controlling shareholding. The company will continue to commercialize the affected brands until September 30, 2026.
Dr Reddys Laboratories Ltd
Dr Reddys Laboratories Ltd has terminated its agreement with Novartis India Limited due to a change in controlling shareholding of NIL. The company will continue to commercialize the affected brands until September 30, 2026.
Dr Reddys Laboratories Ltd
Dr Reddys Laboratories Ltd has terminated its agreement with Novartis India Limited due to a change in controlling shareholding. The company will continue to commercialize the affected brands until September 30, 2026.
Dr Reddys Laboratories Ltd
Dr. Reddy's Laboratories Ltd. has received U.S. FDA approval for its rituximab biosimilar, a biosimilar to Rituxan, for the U.S. market. The approval further strengthens Dr. Reddy's growing global biosimilars portfolio and advances its biosimilars business in the United States.
Dr Reddys Laboratories Ltd
Dr Reddys Laboratories Ltd has informed that the USFDA has completed a Pre-Approval Inspection (PAI) and Good Manufacturing Practices (GMP) inspection at its FTO-SEZ Process Unit-02 in Srikakulam, Andhra Pradesh, and has issued a Form 483 with three observations.
Dr Reddys Laboratories Ltd
Dr Reddy's Laboratories Ltd clarifies a news article published in Business Standard regarding the company's antibiotic getting Thailand approval six months after US nod. The company confirms the accuracy of the news and states that it does not constitute a material event or information requiring disclosure under Regulation 30 of SEBI Listing Regulation.
Dr Reddys Laboratories Ltd
Dr Reddy's Laboratories Ltd reported Q1FY27 revenue decline of 5.6% YoY and EBITDA margin of 12.5%, impacted by lower lenalidomide revenues and provision for semaglutide API related challenges.
Dr Reddys Laboratories Ltd
Dr Reddys Laboratories Ltd has been asked by the exchange to clarify a media report regarding the company's first-in-class gonorrhoea drug receiving approval in Thailand after receiving US nod.
Dr Reddys Laboratories Ltd
Dr. Reddy's Laboratories Ltd. has announced the re-appointment of Dr. K P Krishnan as an Independent Director for a second term of five consecutive years, and the appointment of Mr. Srikanth Velamakanni as an Independent Director for a term of five consecutive years. The company has also appointed M/s Deloitte Haskins & Sells, LLP, Chartered Accountants as Statutory Auditors for a term of five consecutive years.
Dr Reddys Laboratories Ltd
Dr. Reddy's Laboratories Ltd. has announced the outcome of its 42nd Annual General Meeting (AGM), which was held through video conferencing on July 23, 2026. The meeting was attended by 86 members holding 22,25,59,764 shares. The AGM proceedings were conducted in compliance with the applicable Circulars issued by the Ministry of Corporate Affairs (MCA) and Securities and Exchange Board of India (SEBI). The company's Integrated Annual Report for FY2025-26, containing the Notice of the 42nd AGM and the Auditor's Report, was circulated to the members through electronic mode.
Dr Reddys Laboratories Ltd
Dr. Reddy's Laboratories Ltd. held its 42nd Annual General Meeting (AGM) on July 23, 2026, through Video Conferencing (VC) / Other Audio-Visual Means (OAVM). The meeting was conducted in compliance with the General Circular issued by the Ministry of Corporate Affairs (MCA) and circular issued by the Securities and Exchange Board of India (SEBI). The requisite quorum was present, and the meeting was called to order. The Chairman extended a warm welcome to all members and other participants. The Company Secretary informed the members that the meeting is being held through VC/OAVM in compliance with the applicable Circulars issued by the MCA and SEBI. The Integrated Annual Report for FY2025-26 containing the Notice of the 42nd AGM and the Auditor's Report was circulated to the members through electronic mode. The Notice convening the meeting and the Auditor's Report are taken as read. The Chairman delivered his speech followed by the address by the Co-Chairman and Managing Director.
Dr Reddys Laboratories Ltd
Dr Reddys Laboratories Ltd has published unaudited financial results for the quarter ended June 30, 2026, in Business standard and Andhra Prabha newspapers.
Dr Reddys Laboratories Ltd
Dr Reddys Laboratories Ltd has made available the audio recordings of its earnings call for the quarter ended June 30, 2026, as per Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Dr Reddys Laboratories Ltd
Dr. Reddy's Laboratories Ltd. has announced its unaudited financial results for Q1 FY27, with a healthy double-digit base business growth and an EBITDA margin of 15.4% before the semaglutide-related impact. The company has also made significant progress across its strategic priorities, including the launch of new products and partnerships.